NCT04125472Approved For Marketing不适用
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals0 个研究点开始时间: 2019年10月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
研究概览
简要总结
The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),
详细描述
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented diagnosis of Primary Hyperoxaluria Type 1
排除标准
- •Clinically significant health concerns (with the exception of PH1)
- •Received an investigational agent within 30 days before the first dose of lumasiran or are in follow-up of another clinical study
- •Previously or currently participating in lumasiran clinical study
- •History of liver transplant
研究者
相似试验
No Longer Available
不适用
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsSickle Cell DiseaseNCT04724421Pfizer
Available
不适用
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesNCT04457687Eisai Inc.
No Longer Available
不适用
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)Non-small Cell Lung CancerNCT01279798NovaRx Corporation
Available
不适用
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCANCT06034886Biohaven Pharmaceuticals, Inc.
Approved For Marketing
不适用
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, FamilialFamilial Amyloid PolyneuropathiesAmyloid NeuropathiesAmyloidosis, Hereditary, Transthyretin-RelatedNCT02939820Alnylam Pharmaceuticals